FEMYHealthcare · Medical Instruments & SuppliesThe 3 Wall Street analysts covering Femasys, Inc. hold a median 12-month price target of $10 — +471.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 12 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Femasys, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Value (11): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on FEMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +471.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Lake Street | Maintains | Buy | $30 → $10 |
| 14 Aug 2026 | Maxim Group | Maintains | Buy | $30 → $10 |
| 3 Mar 2026 | Lake Street | Initiates | Buy | $1.50 |
| 3 Mar 2026 | Lake Street | Initiates | Buy | — |
| 20 Nov 2025 | Laidlaw & Co. | Initiates | Buy | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2025 | Jones Trading | Maintains | Buy | — |
| 9 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FEMY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, Femasys, Inc. returned −85.7% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 18% of US stocks
Cheaper than 53% of US stocks
Cheaper than 69% of US stocks
Higher than 12% of US stocks
Higher than 21% of US stocks
Higher than 70% of US stocks
Higher than 5% of US stocks
Higher than 97% of US stocks
Higher than 4% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Femasys, Inc. has a market value of $16.8M and an enterprise value of $20.1M.
Revenue in the twelve months to 30 June 2026: $2.3M. The latest quarter shrank 18.9% year on year.
Net income over the same four quarters: −$11.8M, a −511.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$18.2M.
Trailing P/E: −0.2×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Femasys, Inc. employs 51 people — $45K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Femasys, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Femasys announced it will exhibit at the ASRM 2026 Scientific Congress & Expo, taking place October 24–28 in Baltimore. The company plans to feature FemaSeed Intratubal Insemination and FemVue at booth #513.
Why it matters — The appearance gives FEMY watchers information about where and how the company plans to present its fertility and diagnostic products at the congress.
Femasys announced that Minnesota Women's Care will adopt its FemaSeed Complete portfolio and FemVue technology for fertility diagnostic evaluation and in-office first-line fertility treatment across its four OB/GYN practice locations. This marks an advancement in the company's expansion within the OB/GYN market.
Why it matters — A multi-site OB/GYN practice adopting FemVue and FemaSeed across all its locations signals growing commercial uptake of Femasys' fertility products in the clinical market.
Femasys announced a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions. The company described this as a step toward improving standards of care and expanding access to its products.
Why it matters — The partnership could broaden patient access to Femasys' fertility products through financing options, potentially supporting adoption of its FemaSeed portfolio.
Femasys announced a partnership with UNC Health to introduce its fertility portfolio—FemVue, SpermVue, and FemaSeed Complete—into UNC Health OB/GYN practice locations across the system. This marks the first time UNG Health OB/GYNs can offer FemVue evaluation and FemaSeed as first-line treatment options.
Why it matters — FEMY watchers would care because this partnership expands the commercial availability of the company's fertility products within a leading academic health system's OB/GYN practices, advancing Femasys' initiative to bring fertility evaluation and treatment earlier into the care pathway.
The U.S. Food and Drug Administration authorized the modular premarket approval application pathway for FemBloc, Femasys' non-surgical permanent birth control technology. This represents a regulatory milestone for the device.
Why it matters — For FEMY watchers, this establishes a clearer regulatory route for FemBloc, potentially advancing its path toward FDA approval.
The 3 Wall Street analysts covering Femasys, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Femasys, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Femasys, Inc. 43 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Femasys, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +471.4% from the last close, and Ticker Nerd's factor model ranks Femasys, Inc. 43 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Femasys, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FEMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $23 over the next 12 months.
Femasys, Inc. returned -85.7% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Femasys Inc. is a biomedical company focused on women’s reproductive health.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo". Femasys announced it will exhibit at the ASRM 2026 Scientific Congress & Expo, taking place October 24–28 in Baltimore. The company plans to feature FemaSeed Intratubal Insemination and FemVue at booth #513.
Femasys Inc. is a biomedical company focused on women’s reproductive health. The company develops and commercializes accessible, minimally invasive, in-office therapeutic and diagnostic products designed to address unmet needs in fertility care, birth control, and gynecologic testing. Its portfolio includes FemVue for fallopian tube assessment, FemCath for selective tube evaluation, FemCerv for endocervical tissue sampling, FemBloc for non-surgical permanent birth control, and FemaSeed for assisted insemination. Femasys also offers related products and technologies used by physicians and women’s healthcare providers in office-based settings. Headquartered in Suwanee, Georgia, Femasys serves both U.S. and international markets with a focus on improving reproductive healthcare delivery.
CEO Ms. Kathy Lee-Sepsick M.B.A. · 51 employees · United States · https://femasys.com
